רזולור 1 מג ישראל - עברית - Ministry of Health

רזולור 1 מג

biotis ltd - prucalopride as succinate - טבליות מצופות פילם - prucalopride as succinate 1 mg - prucalopride - prucalopride - resolor is indicated for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief

רזולור 2 מג ישראל - עברית - Ministry of Health

רזולור 2 מג

biotis ltd - prucalopride as succinate - טבליות מצופות פילם - prucalopride as succinate 2 mg - prucalopride - prucalopride - resolor is indicated for symptomatic treatment of chronic constipation in women in whom laxatives fail to provide adequate relief

ספזמקס 30 ישראל - עברית - Ministry of Health

ספזמקס 30

tec-o-pharm-libra ltd - trospium chloride - טבליות מצופות פילם - trospium chloride 30 mg - trospium and analgesics - trospium and analgesics - for the treatment of vegetative bladder dysfunction accompanied by urgency and/or frequency and/or urinary incontinence.

זופרן טבליות 8 מג ישראל - עברית - Ministry of Health

זופרן טבליות 8 מג

novartis israel ltd - ondansetron as hydrochloride dihydrate - טבליה - ondansetron as hydrochloride dihydrate 8 mg - ondansetron - ondansetron - for the mangement of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. for prevention and treatment of post operative nausea and vomiting in adults.

זופרן טבליות 4 מג ישראל - עברית - Ministry of Health

זופרן טבליות 4 מג

novartis israel ltd - ondansetron as hydrochloride dihydrate - טבליה - ondansetron as hydrochloride dihydrate 4 mg - ondansetron - ondansetron - management of nausea and vomiting induced by cytotoxic chemotherapy and radiotherapy. for prevention and treatment of post operative nausea and vomiting in adults .

סטרון 1 מג ישראל - עברית - Ministry of Health

סטרון 1 מג

padagis israel agencies ltd, israel - granisetron as hydrochloride - טבליה - granisetron as hydrochloride 1 mg - granisetron - granisetron - prevention of nausea and vomiting induced by cytostatic therapy.

אימנד 80 מג קפסולות ישראל - עברית - Ministry of Health

אימנד 80 מג קפסולות

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

אימנד 80 מג קפסולות ישראל - עברית - Ministry of Health

אימנד 80 מג קפסולות

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

אימנד 80 מג קפסולות ישראל - עברית - Ministry of Health

אימנד 80 מג קפסולות

merck sharp & dohme (israel - 1996) company ltd, israel - aprepitant - קפסולות - aprepitant 80 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.

אימנד 125 מג קפסולות ישראל - עברית - Ministry of Health

אימנד 125 מג קפסולות

merck sharp & dohme israel ltd - aprepitant - קפסולות - aprepitant 125 mg - aprepitant - aprepitant - emend in combination with other antiemetic agents is indicated for the: - prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy including high-dose cisplatin. - prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.